Skip to main content
Livermore
Livermore
中文EN

Erasca, Inc.

ERAS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001761918

No open-market purchases or sales by Erasca, Inc. insiders were filed in the last 90 days; 256 institutions reported holding it in 13F filings for Q2 2026, worth $5.14B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Erasca, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Erasca, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Erasca, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Fuchs Charles S.President, R&D–Aug 12, 20261
Liu Jean IDirector–Jun 29, 20262
Casdin Alexander W.Director573,974Jun 29, 20262
Hambleton JulieDirector6,000Jun 29, 20261
Multani Pratik SDirector6,200IndirectJun 29, 20262
Start Valerie Denise HardingDirector20,000IndirectJun 29, 20262
Bristol James ArthurDirector20,000IndirectJun 29, 20262
Garner EbunChief Legal Officer25,076Apr 3, 20263
Morris ShannonChief Medical Officer0Mar 6, 20262
Lim Jonathan EChairman & CEO12,899,360IndirectJan 30, 20261
Varney Michael DavidDirector–Jan 30, 20261
Chacko David M.CFO and CBO279,980Jan 30, 20261
Cormorant Asset Management, LPDirector10,813,246IndirectJun 26, 20230
Chen BihuaDirector10,813,246IndirectJun 26, 20230
Cormorant Global Healthcare Master Fund, LPDirector10,813,246IndirectJun 26, 20230
Cormorant Private Healthcare Fund II, LPDirector10,813,246IndirectJun 26, 20230
Wei LinChief Medical Officer315,812Feb 3, 20230
City Hill, LLC10% Owner11,899,360IndirectJul 20, 20210
Lim Conyee T.10% Owner11,899,360IndirectJul 20, 20210
Crandell Keith10% Owner5,527,777IndirectJul 20, 20210
Nelsen Robert10% Owner5,527,777IndirectJul 20, 20210
Gillis Steven10% Owner5,527,777IndirectJul 20, 20210
Burow Kristina10% Owner5,527,777IndirectJul 20, 20210
ARCH Venture Fund X, L.P.10% Owner5,527,777IndirectJul 20, 20210
ARCH Venture Fund X Overage, L.P.10% Owner5,527,777IndirectJul 20, 20210
ARCH Venture Partners X Overage, L.P.10% Owner5,527,777IndirectJul 20, 20210
ARCH Venture Partners X, LLC10% Owner5,527,777IndirectJul 20, 20210
ARCH Venture Partners X, L.P.10% Owner5,527,777IndirectJul 20, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Apr 3, 2026 (view filing)Apr 12 daysGarner EbunChief Legal OfficerSSale−80.0K$16.40−$1.31M−76.1%25.1K after10b5-1
Mar 6, 2026 (view filing)Mar 42 daysMorris ShannonChief Medical OfficerSSale−20.0K$15.04−$300.8K−100.0%0 after10b5-1
Jan 8, 2026 (view filing)Jan 71 dayGarner EbunGeneral Counsel & Corp. Sec.SSale−120.0K$5.59−$670.8K−82.7%25.1K after10b5-1
May 22, 2024 (view filing)May 211 dayCasdin Alexander W.DirectorPPurchase+80.0K$2.27+$181.6K+16.2%574.0K after
Dec 8, 2023 (view filing)Dec 62 daysStart Valerie Denise HardingDirectorPPurchase+10.0K$1.85+$18.5K+100.0%20.0K after
Dec 6, 2023 (view filing)Dec 5-61 dayLim Jonathan EChairman & CEOPPurchase+1.00M$1.70+$1.70M+8.4%12.9M after2 lots
Dec 4, 2023 (view filing)Dec 4Same dayCasdin Alexander W.DirectorPPurchase+30.0K$1.66+$49.8K+6.5%494.0K after
Oct 10, 2023 (view filing)Oct 55 daysLim Jonathan EChairman & CEOPPurchase+1.00M$2.03+$2.03M+5.4%19.5M after
Jun 8, 2023 (view filing)Jun 8Same dayLim Jonathan EChairman & CEOPPurchase+100.0K$2.75+$275.0K+0.5%18.4M after
Apr 11, 2023 (view filing)Apr 101 dayCasdin Alexander W.DirectorPPurchase+20.0K$2.76+$55.2K+4.5%464.0K after
Jan 10, 2023 (view filing)Jan 10Same dayLim Jonathan EChairman & CEOPPurchase+60.0K$3.86+$231.6K+0.3%20.3M after
Dec 22, 2022 (view filing)Dec 211 dayStart Valerie Denise HardingDirectorPPurchase+10.0K$4.64+$46.4KNew position10.0K after
Dec 22, 2022 (view filing)Dec 211 dayBristol James ArthurDirectorPPurchase+20.0K$4.14+$82.8KNew position20.0K after
Dec 21, 2022 (view filing)4:33 PM ETDec 138 daysCormorant Asset Management, LP and 3 othersDirectorPPurchase+307.7K$6.50+$2.00M+2.9%10.8M afterAmended
Dec 15, 2022 (view filing)Dec 15Same dayCasdin Alexander W.DirectorPPurchase+20.0K$4.87+$97.4K+4.7%444.0K after
Dec 15, 2022 (view filing)Dec 141 dayLim Jonathan EChairman & CEOPPurchase+40.0K$4.99+$199.6K+0.2%20.2M after
Aug 10, 2021 (view filing)Jul 2615 daysLateChen BihuaDirectorSSale−200.0K$18.77−$3.75M−1.9%10.3M after
Aug 10, 2021 (view filing)Aug 10Same dayChen BihuaDirectorPPurchase+200.0K$22.10+$4.42M+1.9%10.5M after
Jul 22, 2021 (view filing)4:10 PM ETJul 202 daysChen Bihua and 3 othersDirectorPPurchase+950.0K$16.00+$15.2M+9.9%10.5M after
Jul 20, 2021 (view filing)Jul 20Same dayGarner EbunGeneral CounselPPurchase+900$16.00+$14.4KNew position900 after
Jul 20, 2021 (view filing)Jul 20Same dayStart Valerie Denise HardingDirectorPPurchase+2.00K$16.00+$32.0KNew position2.00K after
Jul 20, 2021 (view filing)Jul 20Same dayMultani Pratik SDirectorPPurchase+6.20K$16.00+$99.2K+3.7%172.9K after
Jul 20, 2021 (view filing)Jul 20Same dayHambleton JulieDirectorPPurchase+6.00K$16.00+$96.0KNew position6.00K after